Findings of Research Misconduct, 22497-22498 [2018-10310]
Download as PDF
<![CDATA[
daltland on DSKBBV9HB2PROD with NOTICES
Federal Register / Vol. 83, No. 94 / Tuesday, May 15, 2018 / Notices
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Dockets Management
Staff, 5630 Fishers Lane, Rm. 1061,
Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT:
Lauren D. Tesh, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 31, Rm. 2417,
Silver Spring, MD 20993–0002, 301–
796–9001, Fax: 301–847–8533, email:
ODAC@fda.hhs.gov; or FDA Advisory
Committee Information Line, 1–800–
741–8138 (301–443–0572 in the
Washington, DC area). A notice in the
Federal Register about last minute
modifications that impact a previously
announced advisory committee meeting
cannot always be published quickly
enough to provide timely notice.
Therefore, you should always check the
FDA’s website at https://www.fda.gov/
AdvisoryCommittees/default.htm and
scroll down to the appropriate advisory
committee meeting link, or call the
advisory committee information line to
learn about possible modifications
before coming to the meeting.
SUPPLEMENTARY INFORMATION:
Agenda: The particular matter for this
meeting will be review and discussion
of a list of molecular targets for which
evidence and/or biologic rationale exist
to determine their potential relevance to
the growth or progression of one or
more pediatric cancers and a list of
those targets deemed unlikely to be
associated with the growth or
progression of pediatric tumors. These
lists are expected to fulfill the statutory
obligation of the Food and Drug
Administration Reauthorization Act
(FDARA) and provide some guidance to
industry in planning for initial Pediatric
Study Plan submissions for new drug
and/or biologic products in
development for cancer in accordance
with the amended provisions of the
Pediatric Research Equity Act. The
committee will review and discuss
considerations other than scientific
relevance that FDA will include in
decision making with respect to the
need and timing of pediatric evaluation
of specific new drug and biologic
products. The committee will discuss
possible criteria and mechanisms for the
prioritization by sponsors and the
clinical investigator community of
select targeted new agents for pediatric
evaluation especially in the setting of
multiple same in class agents.
Preliminary discussion will focus on
approaches to coordination and
collaboration for pediatric clinical
investigations of new agents that might
VerDate Sep<11>2014
20:27 May 14, 2018
Jkt 244001
be pursued to efficiently accommodate
international regulatory requirements
and global pediatric product
development. The open public hearing
sessions are: Topic 1: Target List, Topic
2: FDARA Implementation, and Topic 3:
Mechanisms to Assure Efficiency and to
Enhance Global Coordination Through
International Collaboration.
FDA intends to make background
material available to the public no later
than 2 business days before the meeting.
If FDA is unable to post the background
material on its website prior to the
meeting, the background material will
be made publicly available at the
location of the advisory committee
meeting, and the background material
will be posted on FDA’s website after
the meeting. Background material is
available at https://www.fda.gov/
AdvisoryCommittees/Calendar/
default.htm. Scroll down to the
appropriate advisory committee meeting
link.
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the subcommittee. All electronic
and written submissions submitted to
the Docket (see ADDRESSES) on or before
June 5, 2018, will be provided to the
subcommittee. Oral presentations from
the public will be scheduled between
approximately 10:25 a.m. and 10:45
a.m., 1:40 p.m. and 2 p.m., and 3:40
p.m. and 4:30 p.m. Those individuals
interested in making formal oral
presentations should notify the contact
person and submit a brief statement of
the general nature of the evidence or
arguments they wish to present, the
names and addresses of proposed
participants, and an indication of the
approximate time requested to make
their presentation on or before May 25,
2018. Time allotted for each
presentation may be limited. If the
number of registrants requesting to
speak is greater than can be reasonably
accommodated during the scheduled
open public hearing session, FDA may
conduct a lottery to determine the
speakers for the scheduled open public
hearing session. The contact person will
notify interested persons regarding their
request to speak by May 29, 2018.
Persons attending FDA’s advisory
committee meetings are advised that
FDA is not responsible for providing
access to electrical outlets.
For press inquiries, please contact the
Office of Media Affairs at fdaoma@
fda.hhs.gov or 301–796–4540.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with disabilities.
If you require accommodations due to a
PO 00000
Frm 00057
Fmt 4703
Sfmt 4703
22497
disability, please contact Lauren D. Tesh
(see FOR FURTHER INFORMATION CONTACT)
at least 7 days in advance of the
meeting.
FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our website at
https://www.fda.gov/
AdvisoryCommittees/
AboutAdvisoryCommittees/
ucm111462.htm for procedures on
public conduct during advisory
committee meetings.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: May 9, 2018.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2018–10337 Filed 5–14–18; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
Office of the Secretary, HHS.
Notice.
AGENCY:
ACTION:
Findings of research
misconduct have been made on the part
of Gareth John, Ph.D., Professor,
Department of Neurology, Icahn School
of Medicine at Mount Sinai (ISMMS).
Dr. John engaged in research
misconduct in research supported by
National Institute of Neurological
Disorders and Stroke (NINDS), National
Institutes of Health (NIH), grants R01
NS056074 and R01 NS062703. The
administrative actions, including one (1)
year of supervision, were implemented
beginning on April 26, 2018, and are
detailed below.
FOR FURTHER INFORMATION CONTACT:
Wanda K. Jones, Dr.P.H., Interim
Director, Office of Research Integrity,
1101 Wootton Parkway, Suite 750,
Rockville, MD 20852, (240) 453–8200.
SUPPLEMENTARY INFORMATION: Notice is
hereby given that the Office of Research
Integrity (ORI) has taken final action in
the following case:
Gareth John, Ph.D., Icahn School of
Medicine at Mount Sinai: Based on
Respondent’s admission, the report of
an inquiry and investigation conducted
by ISMMS, and additional analysis
conducted by ORI in its oversight
review, ORI found that Dr. Gareth John,
Professor, Department of Neurology,
ISMMS, engaged in research
misconduct in research supported by
NINDS, NIH, grants R01 NS056074 and
R01 NS062703.
SUMMARY:
E:\FR\FM\15MYN1.SGM
15MYN1
daltland on DSKBBV9HB2PROD with NOTICES
22498
Federal Register / Vol. 83, No. 94 / Tuesday, May 15, 2018 / Notices
ORI found that Respondent engaged
in research misconduct by knowingly
and intentionally falsifying data
reported in Development 141(12):2414–
28, 2014 Jun (hereafter referred to as
‘‘Development 2014’’).
In addition to making an admission,
Respondent cooperated fully with
ISMMS and ORI and has expressed
remorse for his actions.
Specifically, ORI found that
Respondent:
• used the p-GSK3a/b double bands
in Figure S3B of Development 2014,
removed the lower set of bands,
reordered the remaining bands and used
those bands to represent the actin
control in an experiment comparing the
impact of Tgfb1 and ActB individually
and in combination in primary
oligodendrocyte progenitors (OLPs) and
the oligodendrocyte-derived Oli-Neu
cell line.
• used the densitometry readings
from the falsified actin bands in Figure
S3B of Development 2014 to compare
the density of A+T, Tgfb1, ActB, and
Veh relative to the false actin signal in
Figure S3C–J, creating eight false
graphs.
• falsified the bands representing
Myelin basic protein (Mbp) in Figure 3C
of Development 2014 by cutting and
pasting the bands onto a blank
background and used those false bands
to create a graph showing the density of
Mbp in the presence and absence of
ActB, Tgfb1, and Bmp4.
As a result of this admission,
Respondent has notified Development
that corrections to figures in the paper,
but not to the text, including the
conclusions in Development 2014 are
required.
Dr. John entered into a Voluntary
Settlement Agreement and voluntarily
agreed, beginning on April 26, 2018:
(1) To have his research supervised
for a period of one (1) year; Respondent
agreed that prior to submission of an
application for U.S. Public Health
Service (PHS) support for a research
project on which the Respondent’s
participation is proposed and prior to
Respondent’s participation in any
capacity on PHS-supported research,
Respondent shall ensure that a plan for
supervision of Respondent’s duties is
submitted to ORI for approval; the
supervision plan must be designed to
ensure the scientific integrity of
Respondent’s research contribution;
Respondent agreed that he shall not
participate in any PHS-supported
research until such a supervision plan is
submitted to and approved by ORI;
Respondent agreed to maintain
responsibility for compliance with the
agreed upon supervision plan;
VerDate Sep<11>2014
20:27 May 14, 2018
Jkt 244001
(2) that for one (1) year, any
institution employing him shall submit,
in conjunction with each application for
PHS funds, or report, manuscript, or
abstract involving PHS-supported
research in which Respondent is
involved, a certification to ORI that the
data provided by Respondent are based
on actual experiments or are otherwise
legitimately derived and that the data,
procedures, and methodology are
accurately reported in the application,
report, manuscript, or abstract;
(3) if no supervisory plan is provided
to ORI, to provide certification to ORI at
the conclusion of the supervision period
that he has not engaged in, applied for,
or had his name included on any
application, proposal, or other request
for PHS funds without prior notification
to ORI;
(4) to exclude himself voluntarily
from serving in any advisory capacity to
PHS including, but not limited to,
service on any PHS advisory committee,
board, and/or peer review committee, or
as a consultant for a period of one (1)
year; and
(5) to follow up with the journal
editor regarding his previous request to
correct the following paper to ensure
that the corrections are made:
• Development 141(12):2414–28,
2014 Jun.
Wanda K. Jones,
Interim Director, Office of Research Integrity.
[FR Doc. 2018–10310 Filed 5–14–18; 8:45 am]
BILLING CODE 4150–31–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of Microbiology, Infectious
Diseases and AIDS Initial Review Group
Microbiology and Infectious Diseases
Research Committee.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
PO 00000
Frm 00058
Fmt 4703
Sfmt 4703
Name of Committee: Microbiology,
Infectious Diseases and AIDS Initial Review
Group Microbiology and Infectious Diseases
Research Committee.
Date: June 7–8, 2018.
Time: 9:30 a.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 5601
Fishers Lane, Rockville, MD 20892
(Telephone Conference Call).
Contact Person: Frank S. De Silva, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
Room #3E72A, National Institutes of Health/
NIAID, 5601 Fishers Lane, MSC 9834,
Bethesda, MD 20892934, (240) 669–5023,
fdesilva@niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: May 10, 2018.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–10316 Filed 5–14–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Biomedical
Imaging and Bioengineering; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
meeting of the National Institute of
Biomedical Imaging and Bioengineering
Special Emphasis Panel.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Biomedical Imaging and Bioengineering
Special Emphasis Panel; P41 BTRC Review
(2018/10).
Date: July 5–7, 2018.
Time: 6:00 p.m. to 1:00 p.m.
Agenda: To review and evaluate grant
applications and/or proposals.
Place: Courtyard by Marriott New York
Manhattan/Upper ES, 410 East 92nd Street,
New York, NY 10128.
Contact Person: Manana Sukhareva, Ph.D.,
Scientific Review Officer, National Institute
E:\FR\FM\15MYN1.SGM
15MYN1
]]>Agencies
[Federal Register Volume 83, Number 94 (Tuesday, May 15, 2018)]
[Notices]
[Pages 22497-22498]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-10310]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
AGENCY: Office of the Secretary, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Findings of research misconduct have been made on the part of
Gareth John, Ph.D., Professor, Department of Neurology, Icahn School of
Medicine at Mount Sinai (ISMMS).
Dr. John engaged in research misconduct in research supported by
National Institute of Neurological Disorders and Stroke (NINDS),
National Institutes of Health (NIH), grants R01 NS056074 and R01
NS062703. The administrative actions, including one (1) year of
supervision, were implemented beginning on April 26, 2018, and are
detailed below.
FOR FURTHER INFORMATION CONTACT:
Wanda K. Jones, Dr.P.H., Interim Director, Office of Research
Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240)
453-8200.
SUPPLEMENTARY INFORMATION: Notice is hereby given that the Office of
Research Integrity (ORI) has taken final action in the following case:
Gareth John, Ph.D., Icahn School of Medicine at Mount Sinai: Based
on Respondent's admission, the report of an inquiry and investigation
conducted by ISMMS, and additional analysis conducted by ORI in its
oversight review, ORI found that Dr. Gareth John, Professor, Department
of Neurology, ISMMS, engaged in research misconduct in research
supported by NINDS, NIH, grants R01 NS056074 and R01 NS062703.
[[Page 22498]]
ORI found that Respondent engaged in research misconduct by
knowingly and intentionally falsifying data reported in Development
141(12):2414-28, 2014 Jun (hereafter referred to as ``Development
2014'').
In addition to making an admission, Respondent cooperated fully
with ISMMS and ORI and has expressed remorse for his actions.
Specifically, ORI found that Respondent:
used the p-GSK3[alpha]/[beta] double bands in Figure S3B
of Development 2014, removed the lower set of bands, reordered the
remaining bands and used those bands to represent the actin control in
an experiment comparing the impact of Tgf[beta]1 and ActB individually
and in combination in primary oligodendrocyte progenitors (OLPs) and
the oligodendrocyte-derived Oli-Neu cell line.
used the densitometry readings from the falsified actin
bands in Figure S3B of Development 2014 to compare the density of A+T,
Tgf[beta]1, ActB, and Veh relative to the false actin signal in Figure
S3C-J, creating eight false graphs.
falsified the bands representing Myelin basic protein
(Mbp) in Figure 3C of Development 2014 by cutting and pasting the bands
onto a blank background and used those false bands to create a graph
showing the density of Mbp in the presence and absence of ActB,
Tgf[beta]1, and Bmp4.
As a result of this admission, Respondent has notified Development
that corrections to figures in the paper, but not to the text,
including the conclusions in Development 2014 are required.
Dr. John entered into a Voluntary Settlement Agreement and
voluntarily agreed, beginning on April 26, 2018:
(1) To have his research supervised for a period of one (1) year;
Respondent agreed that prior to submission of an application for U.S.
Public Health Service (PHS) support for a research project on which the
Respondent's participation is proposed and prior to Respondent's
participation in any capacity on PHS-supported research, Respondent
shall ensure that a plan for supervision of Respondent's duties is
submitted to ORI for approval; the supervision plan must be designed to
ensure the scientific integrity of Respondent's research contribution;
Respondent agreed that he shall not participate in any PHS-supported
research until such a supervision plan is submitted to and approved by
ORI; Respondent agreed to maintain responsibility for compliance with
the agreed upon supervision plan;
(2) that for one (1) year, any institution employing him shall
submit, in conjunction with each application for PHS funds, or report,
manuscript, or abstract involving PHS-supported research in which
Respondent is involved, a certification to ORI that the data provided
by Respondent are based on actual experiments or are otherwise
legitimately derived and that the data, procedures, and methodology are
accurately reported in the application, report, manuscript, or
abstract;
(3) if no supervisory plan is provided to ORI, to provide
certification to ORI at the conclusion of the supervision period that
he has not engaged in, applied for, or had his name included on any
application, proposal, or other request for PHS funds without prior
notification to ORI;
(4) to exclude himself voluntarily from serving in any advisory
capacity to PHS including, but not limited to, service on any PHS
advisory committee, board, and/or peer review committee, or as a
consultant for a period of one (1) year; and
(5) to follow up with the journal editor regarding his previous
request to correct the following paper to ensure that the corrections
are made:
Development 141(12):2414-28, 2014 Jun.
Wanda K. Jones,
Interim Director, Office of Research Integrity.
[FR Doc. 2018-10310 Filed 5-14-18; 8:45 am]
BILLING CODE 4150-31-P
